Table of Contents
Pathology Research International
Volume 2011, Article ID 167046, 11 pages
http://dx.doi.org/10.4061/2011/167046
Research Article

Effects of the Demethylating Agent, 5-Azacytidine, on Expression of the Kallikrein-Kinin Genes in Carcinoma Cells of the Lung and Pleura

Lung Institute of Western Australia and Centre for Asthma, Allergy and Respiratory Research, The University of Western Australia, Ground Floor, E Block, Sir Charles Gairdner Hospital, Perth, WA 6009, Australia

Received 14 December 2010; Accepted 12 June 2011

Academic Editor: Allen Burke

Copyright © 2011 Joshua Wong et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. G. Schwartz, G. M. Prysak, C. H. Bock, and M. L. Cote, “The molecular epidemiology of lung cancer,” Carcinogenesis, vol. 28, no. 3, pp. 507–518, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  2. A. Risch and C. Plass, “Lung cancer epigenetics and genetics,” International Journal of Cancer, vol. 123, no. 1, pp. 1–7, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  3. B. P. Shelton, N. L. Misso, O. M. Shaw, E. Arthaningtyas, and K. D. Bhoola, “Epigenetic regulation of human epithelial cell cancers,” Current Opinion in Molecular Therapeutics, vol. 10, no. 6, pp. 568–578, 2008. View at Google Scholar · View at Scopus
  4. J. T. Hodgson and A. Darnton, “The quantitative risks of mesothelioma and lung cancer in relation to asbestos exposure,” Annals of Occupational Hygiene, vol. 44, no. 8, pp. 565–601, 2000. View at Google Scholar · View at Scopus
  5. M. Gulumian and T. A. Kilroe-Smith, “Crocidolite-induced lipid peroxidation in rat lung microsomes. I. Role of different ions,” Environmental Research, vol. 43, no. 1, pp. 267–273, 1987. View at Google Scholar · View at Scopus
  6. D. W. Kamp, P. Graceffa, A. W. Pryor, and S. A. Weitzman, “The role of free radicals in asbestos-induced diseases,” Free Radical Biology and Medicine, vol. 12, no. 4, pp. 293–315, 1992. View at Publisher · View at Google Scholar · View at Scopus
  7. K. Bhoola, R. Ramsaroop, J. Plendl, B. Cassim, Z. Dlamini, and S. Naicker, “Kallikrein and kinin receptor expression in inflammation and cancer,” Biological Chemistry, vol. 382, no. 1, pp. 77–89, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  8. J. A. Clements, J. Hooper, Y. Dong, and T. Harvey, “The expanded human kallikrein (KLK) gene family: genomic organisation, tissue-specific expression and potential functions,” Biological Chemistry, vol. 382, no. 1, pp. 5–14, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  9. J. A. Clements, N. M. Willemsen, S. A. Myers, and Y. Dong, “The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers,” Critical Reviews in Clinical Laboratory Sciences, vol. 41, no. 3, pp. 265–312, 2004. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  10. E. P. Diamandis and G. M. Yousef, “Human tissue kallikreins: a family of new cancer biomarkers,” Clinical Chemistry, vol. 48, no. 8, pp. 1198–1205, 2002. View at Google Scholar · View at Scopus
  11. C. A. Borgono, I. P. Michael, and E. P. Diamandis, “Human tissue kallikreins: physiologic roles and applications in cancer,” Molecular Cancer Research, vol. 2, no. 5, pp. 257–280, 2004. View at Google Scholar · View at Scopus
  12. J. S. Taub, R. Guo, L. M. Leeb-Lundberg, J. F. Madden, and Y. Daaka, “Bradykinin receptor subtype 1 expression and function in prostate cancer,” Cancer Research, vol. 63, no. 9, pp. 2037–2041, 2003. View at Google Scholar · View at Scopus
  13. R. A. Roberts and W. J. Gullick, “Bradykinin receptor number and sensitivity to ligand stimulation of mitogenesis is increased by expression of a mutant ras oncogene,” Journal of Cell Science, vol. 94, part 3, pp. 527–535, 1989. View at Google Scholar · View at Scopus
  14. A. Graness, A. Adomeit, R. Heinze, R. Wetzker, and C. Liebmann, “A novel signalling pathway of bradykinin in the human colon carcinoma cell line SW-480 involves sequential activation of Gq/11 protein, phosphatidylinositol 3-kinase β, and protein kinase C ε,” Journal of Biological Chemistry, vol. 273, no. 48, pp. 32016–32022, 1998. View at Publisher · View at Google Scholar
  15. J. M. Stewart, L. Gera, D. C. Chan, E. T. Whalley, W. L. Hanson, and J. S. Zuzack, “Potent, long-acting, orally-active bradykinin antagonists for a wide range of applications,” Immunopharmacology, vol. 36, no. 2–3, pp. 167–172, 1997. View at Publisher · View at Google Scholar · View at Scopus
  16. D. C. Chan, L. Gera, J. M. Stewart et al., “Bradykinin antagonist dimer, CU201, inhibits the growth of human lung cancer cell lines in vitro and in vivo and produces synergistic growth inhibition in combination with other antitumor agents,” Clinical Cancer Research, vol. 8, no. 5, pp. 1280–1287, 2002. View at Google Scholar · View at Scopus
  17. J. Chee, A. Naran, N. L. Misso, P. J. Thompson, and K. D. Bhoola, “Expression of tissue and plasma kallikreins and kinin B1 and B2 receptors in lung cancer,” Biological Chemistry, vol. 389, no. 9, pp. 1225–1233, 2008. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  18. J. Chee, J. Singh, A. Naran, N. L. Misso, P. J. Thompson, and K. D. Bhoola, “Novel expression of kallikreins, kallikrein-related peptidases and kinin receptors in human pleural mesothelioma,” Biological Chemistry, vol. 388, no. 11, pp. 1235–1242, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  19. D. Hanahan and R. A. Weinberg, “The hallmarks of cancer,” Cell, vol. 100, no. 1, pp. 57–70, 2000. View at Google Scholar · View at Scopus
  20. A. Miremadi, M. Z. Oestergaard, P. D. Pharoah, and C. Caldas, “Cancer genetics of epigenetic genes,” Human Molecular Genetics, vol. 16, no. 1, pp. R28–R49, 2007. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  21. P. A. Jones and S. B. Baylin, “The fundamental role of epigenetic events in cancer,” Nature Reviews Genetics, vol. 3, no. 6, pp. 415–428, 2002. View at Google Scholar · View at Scopus
  22. K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-(ΔΔC(T)) method,” Methods, vol. 25, no. 4, pp. 402–408, 2001. View at Publisher · View at Google Scholar · View at PubMed · View at Scopus
  23. N. Kitamura, Y. Takagaki, S. Furuto, T. Tanaka, H. Nawa, and S. Nakanishi, “A single gene for bovine high molecular weight and low molecular weight kininogens,” Nature, vol. 305, no. 5934, pp. 545–549, 1983. View at Google Scholar
  24. C. J. Sherr, “Principles of tumor suppression,” Cell, vol. 116, no. 2, pp. 235–246, 2004. View at Publisher · View at Google Scholar
  25. D. Srinivasan, A. H. Kosaka, D. V. Daniels, A. P. Ford, and A. Bhattacharya, “Pharmacological and functional characterization of bradykinin B2 receptor in human prostate,” European Journal of Pharmacology, vol. 504, no. 3, pp. 155–167, 2004. View at Publisher · View at Google Scholar · View at PubMed
  26. J. K. Wright, J. H. Botha, and S. Naidoo, “Influence of the kallikrein-kinin system on prostate and breast tumour angiogenesis,” Tumor Biology, vol. 29, no. 2, pp. 130–136, 2008. View at Publisher · View at Google Scholar · View at PubMed
  27. L. M. Leeb-Lundberg, F. Marceau, W. Müller-Esterl, D. J. Pettibone, and B. L. Zuraw, “International union of pharmacology. XLV. Classification of the kinin receptor family: from molecular mechanisms to pathophysiological consequences,” Pharmacological Reviews, vol. 57, no. 1, pp. 27–77, 2005. View at Publisher · View at Google Scholar · View at PubMed
  28. D. R. Bachvarov, S. Houle, M. Bachvarova, J. Bouthillier, A. Adam, and F. Marceau, “Bradykinin B(2) receptor endocytosis, recycling, and down-regulation assessed using green fluorescent protein conjugates,” Journal of Pharmacology and Experimental Therapeutics, vol. 297, no. 1, pp. 19–26, 2001. View at Google Scholar
  29. J. Enquist, C. Skröder, J. L. Whistler, and L. M. Leeb-Lundberg, “Kinins promote B2 receptor endocytosis and delay constitutive B1 receptor endocytosis,” Molecular Pharmacology, vol. 71, no. 2, pp. 494–507, 2007. View at Publisher · View at Google Scholar · View at PubMed
  30. L. E. Koppelmann, T. C. Moore, and D. D. Porter, “Increased plasma kallikrein activity and tumour growth suppression associated with intralesional bradykinin injections in hamsters,” Journal of Pathology, vol. 126, no. 1, pp. 1–10, 1978. View at Google Scholar
  31. L. O. Dannenberg and H. J. Edenberg, “Epigenetics of gene expression in human hepatoma cells: expression profiling the response to inhibition of DNA methylation and histone deacetylation,” BMC Genomics, vol. 7, p. 181, 2006. View at Publisher · View at Google Scholar · View at PubMed
  32. K. Roder, M. J. Latasa, and H. S. Sul, “Silencing of the mouse H-rev107 gene encoding a class II tumor suppressor by CpG methylation,” Journal of Biological Chemistry, vol. 277, no. 34, pp. 30543–30550, 2002. View at Publisher · View at Google Scholar · View at PubMed
  33. Y. Kitagawa, S. Kyo, M. Takakura et al., “Demethylating reagent 5-azacytidine inhibits telomerase activity in human prostate cancer cells through transcriptional repression of hTERT,” Clinical Cancer Research, vol. 6, no. 7, pp. 2868–2875, 2000. View at Google Scholar
  34. B.-Z. Yuan, A. M. Jefferson, N. C. Popescut, and S. H. Reynolds, “Aberrant gene expression in human non small cell lung carcinoma cells exposed to demethylating agent 5-Aza-2′-deoxycytidine,” Neoplasia, vol. 6, no. 4, pp. 412–419, 2004. View at Google Scholar
  35. G. Pampalakis, E. P. Diamandis, and G. Sotiropoulou, “The epigenetic basis for the aberrant expression of kallikreins in human cancers,” Biological Chemistry, vol. 387, no. 6, pp. 795–799, 2006. View at Publisher · View at Google Scholar · View at PubMed
  36. L. Menendez, D. Walker, L. V. Matyunina et al., “Identification of candidate methylation-responsive genes in ovarian cancer,” Molecular Cancer, vol. 6, p. 10, 2007. View at Publisher · View at Google Scholar · View at PubMed
  37. G. Pampalakis, L. Kurlender, E. P. Diamandis, and G. Sotiropoulou, “Cloning and characterization of novel isoforms of the human kallikrein 6 gene,” Biochemical and Biophysical Research Communications, vol. 320, no. 1, pp. 54–61, 2004. View at Publisher · View at Google Scholar · View at PubMed
  38. S. Mitsui, T. Nakamura, A. Okui, K. Kominami, H. Uemura, and N. Yamaguchi, “Multiple promoters regulate tissue-specific alternative splicing of the human kallikrein gene, KLK11/hippostasin,” FEBS Journal, vol. 273, no. 16, pp. 3678–3686, 2006. View at Publisher · View at Google Scholar · View at PubMed
  39. M. G. Goll and T. H. Bestor, “Eukaryotic cytosine methyltransferases,” Annual Review of Biochemistry, vol. 74, pp. 481–514, 2005. View at Publisher · View at Google Scholar · View at PubMed
  40. C. G. Spilianakis, M. D. Lalioti, T. Town, G. R. Lee, and R. A. Flavell, “Interchromosomal associations between alternatively expressed loci,” Nature, vol. 435, no. 7042, pp. 637–645, 2005. View at Publisher · View at Google Scholar · View at PubMed
  41. A. P. Feinberg, R. Ohlsson, and S. Henikoff, “The epigenetic progenitor origin of human cancer,” Nature Reviews Genetics, vol. 7, no. 1, pp. 21–33, 2006. View at Publisher · View at Google Scholar · View at PubMed